Andrew Cope, MD

Professor, Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London

Articles by Andrew Cope, MD

Abatacept May Delay RA Onset for Up to 4 Years in At-Risk Individuals, With Andrew Cope, MD, PhD

ByAndrew Cope, MD

April 20th 2026

Extended follow-up from the APIPPRA trial also shows evidence of potentially longer protection in the highest-risk subgroup carrying multiple autoantibodies.

Andrew Cope, MD

Articles by Andrew Cope, MD

Abatacept May Delay RA Onset for Up to 4 Years in At-Risk Individuals, With Andrew Cope, MD, PhD

Latest Updated Articles

Trending on Rheumatology Live

Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-Head

Sonelokimab Reduces Inflammation, Osteoblastic Activity in Phase 2 Proof-of-Concept axSpA Study

OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhD

Nipocalimab Demonstrates Proof of Concept for FcRn Blockade for SLE

Nerandomilast Slows Lung Function Decline, Reduces Mortality Risk in Autoimmune ILD Subgroup